skip to Main Content

Instead of providing you with a conventional lecture, early morning workshops allow for active interaction with all attendees (maximum of 60 seats per workshop). Speakers will present a short introduction to the field exposing the major points of research, and controversy in order to initiate the debate with the audience.

IMPORTANT: Pre-registration is compulsory if you wish to attend the Early Morning Workshop. A fee of EUR 24.20 (21% VAT included) is applied. Only participants registered to the ILC may sign up for the Early Morning Workshop sessions. Places are limited so book your seat now!

The discussion will be co-chaired enabling delegates to gain knowledge from different experts in the field, and EASL encourages the participation of Young Investigators (YI) allowing YI poster presenters to present their data during these workshops.

  • Extracellular vesicles in liver pathophysiology
  • Disease modifying treatment in cirrhosis: preventing complications and improving survival (sold out)
  • Occult, covert and over hepatic encephalopathy – practical management
  • Intermediate stage hepatocellular carcinoma: Treatment options
  • Advances in the knowledge and management of cholangiocarcinoma
  • Management of toxicity and long-term effects of immunosuppression
  • New therapeutic approaches in PBC
  • What’s new in drug-induced liver injury
  • Alcoholic liver disease: Role of governmental policies
  • Challenges in the treatment of decompensated HCV-related cirrhosis
  • Practical managment of drug-drug intercation in patients treated with DAA
  • Imaging and elastography for risk stratification in alcoholic liver disease
  • Role of autophagy in liver fibrosis and regeneration
  • Antibiotic therapy in cirrhosis: A challenging balance between efficacy and antibiotic resistance
  • Invasive interventions on patients with portal hypertension
  • Imaging and management of benign liver lesions
  • Immunotherapy in HCC
  • NAFLD screening practices
  • HBV: Should we treat immunotolerant patients?
  • HEV: East vs. West
  • Surveillance of cholangiocarcinoma in PSC
  • Specialist vs. non-specialist care – how will this evolve as the type of patient changes over time